Welcome to our dedicated page for Iovance Biotherp news (Ticker: IOVA), a resource for investors and traders seeking the latest updates and insights on Iovance Biotherp stock.
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) is a biotechnology company focused on innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) cell therapies for patients with cancer. This news page aggregates company announcements, clinical updates, regulatory developments, and financial disclosures related to Iovance’s TIL platform and commercial activities.
Readers can find news about Amtagvi, which Iovance describes as the first FDA-approved T cell therapy for a solid tumor indication, as well as updates on its use in advanced melanoma and other solid tumors. Coverage includes information on Health Canada’s conditional approval of Amtagvi for certain patients with unresectable or metastatic melanoma, and ongoing work to expand access through treatment centers and international markets.
The feed also features interim data from key clinical trials, such as registrational Phase 2 studies of lifileucel in advanced non-small cell lung cancer and other solid tumors, along with reports on next-generation programs like gene-edited TIL therapies and modified IL-2 analogs. Corporate news items include quarterly financial result announcements, conference presentations, equity inducement grants under Nasdaq Listing Rule 5635(c)(4), and capital markets transactions described in SEC filings.
Investors, analysts, and healthcare professionals can use this page to follow how Iovance communicates progress on its TIL pipeline, commercial execution for Amtagvi and Proleukin, and interactions with regulators. Regularly reviewing these updates provides context on the company’s development trajectory and its efforts to advance TIL-based immuno-oncology therapies.
Iovance Biotherapeutics will host a webcast on November 13, 2021 at 5:30 p.m. ET to present updates on its tumor-infiltrating lymphocyte (TIL) therapies in lung cancer and in combination with pembrolizumab. The conference will include insights from key leaders in the field. Additionally, posters will be presented at the SITC Annual Meeting from November 12-14, 2021, detailing phase 2 data for TIL therapy. Iovance aims to pioneer TIL cell therapies, with the potential first one-time cell therapy for solid tumors.
Iovance Biotherapeutics has announced key clinical data presentations at the SITC 36th Annual Meeting on TIL cell therapies for advanced cancers. An oral presentation on November 13 will focus on phase 2 results of TIL in combination with pembrolizumab for immune checkpoint inhibitor-naïve patients. Additionally, posters will cover TIL monotherapy efficacy in NSCLC and advancements in TIL manufacturing. These developments highlight Iovance's commitment to pioneering cancer immunotherapy.
Summary not available.
Iovance Biotherapeutics has announced the successful infusion of the first patient with TIL cell therapy LN-145, produced at the Iovance Cell Therapy Center (iCTC). This milestone is part of the IOV-COM-202 study focusing on metastatic non-small cell lung cancer. The state-of-the-art iCTC facility in Philadelphia aims to meet the demand for TIL therapies, with capacity for thousands of patients. The company plans to balance internal and external TIL manufacturing, prioritizing accessibility and cost reduction for its therapies.
Iovance Biotherapeutics reported its second quarter 2021 financial results, highlighting advances in TIL therapy for cancer. The company has a cash position of $708.7 million as of June 30, sufficient to fund operations through 2023. Key clinical data was presented, showing an 86% overall response rate for lifileucel in combination with pembrolizumab for anti-PD-1 naïve melanoma. However, the net loss for Q2 was $81.4 million, an increase from $63 million in Q2 2020, with R&D expenses rising to $62.1 million.
Iovance Biotherapeutics (NASDAQ: IOVA) is set to release its second quarter financial results on August 5, 2021. The company, focused on T cell-based cancer therapies, will also provide a corporate update during a conference call at 4:30 p.m. ET. Iovance's innovative Tumor Infiltrating Lymphocyte (TIL) therapy targets solid tumors and blood cancers, with ongoing studies in metastatic melanoma and cervical cancer. Future clinical studies aim to evaluate TIL in earlier-stage cancers and blood cancers. Key details about the call are accessible on the Iovance website.
Iovance Biotherapeutics (NASDAQ: IOVA) announced a conference call on June 29, 2021, to discuss recent clinical data for its LN-145 TIL therapy targeting non-small cell lung cancer (NSCLC). The company aims to enhance patient care through T cell-based immunotherapies that utilize tumor-infiltrating lymphocytes (TILs) from patients' own tumors. Iovance is also engaged in pivotal programs for metastatic melanoma and cervical cancer, with ongoing studies for other cancers, demonstrating a strong commitment to advancing cancer treatment.
Iovance Biotherapeutics (NASDAQ: IOVA) announced promising clinical results for its TIL therapy LN-145 in relapsed/refractory metastatic non-small cell lung cancer (mNSCLC). The ongoing study showed a 21.4% overall response rate and a 64.3% disease control rate among patients previously treated with immunotherapies. Notably, the median duration of response was not reached within an 8.2-month follow-up. The company also initiated a registration-supporting trial, IOV-LUN-202, for LN-145 in second-line mNSCLC, aiming to address significant unmet medical needs.
Iovance Biotherapeutics (NASDAQ: IOVA) has announced updated clinical data for lifileucel in advanced melanoma at the ASCO 2021 Annual Meeting. The median duration of response (DOR) for Cohort 2 is not yet reached at 33.1 months, with an overall response rate of 36.4%. Early intervention with lifileucel after anti-PD-1 therapy shows promise for better treatment outcomes. A study indicates that shorter prior anti-PD-1 therapy duration correlates with nearly doubled DOR. Safety profiles remain consistent with previous data, showing no new risks.
Iovance Biotherapeutics (NASDAQ: IOVA) announced promising clinical data for its T cell-based therapy, lifileucel, in combination with pembrolizumab for advanced melanoma patients naïve to immune checkpoint inhibitors. In the IOV-COM-202 study, the initial cohort of 7 patients exhibited an overall response rate (ORR) of 86%, with 43% achieving complete responses. Early responses were durable, and safety profiles were consistent with known therapies. Iovance will host a call on June 6 to discuss the data further, demonstrating its commitment to advancing immunotherapy for cancer treatment.
FAQ
What is the current stock price of Iovance Biotherp (IOVA)?
What is the market cap of Iovance Biotherp (IOVA)?
